The present invention relates to quinazolinones of formula (I) wherein
R.sup.1 is hal; a); b); or c); X is N or CR.sup.8; R.sup.2 is hal; nitro;
C.sub.1-C.sub.6alkylcarbonyl; C.sub.1-C.sub.6alkyl or
C.sub.3-C.sub.6cycloalkyl; R.sup.3 is C.sub.1-C.sub.6alkyl;
C.sub.1-C.sub.6alkoxy or amino; and wherein the further radicals have the
meanings as defined in the specification, which compounds exhibit human
vanilloid antagonistic activity; to processes for their production, their
use as pharmaceuticals and to pharmaceutical compositions comprising
them.